A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis

作者：Wu, Fei; Fan, Xingjuan; Yue, Yan; Xiong, Sidong; Dong, Chunsheng^*

来源：Vaccine, 2014, 32(31): 3917-3926.

DOI：10.1016/j.vaccine.2014.05.052

• Coxsackievirus B3
• Vesicular stomatitis virus
• Viral myocarditis
• Dendritic cell
• Polyfunctional T cells
• Mucosal vaccine

Recombinant vesicular stomatitis virus (VSV) is widely used as a vaccine platform. However, the capacity of VSV-based vaccines to induce mucosal immunity has not been fully investigated. In the present study, a recombinant VSV expressing coxsackievirus B3 (CVB3) major immunogen VP1 has been generated and the immune protection elicited by VSV-VP1 was evaluated. We demonstrated that intranasal delivery of VSV-VP1 can induce a potent antigen-specific mucosal immune response as well as a systemic immune response, particularly the induction of polyfunctional T cells. Importantly, mice immunized with VSV-VP1 were better protected against CVB3-induced viral myocarditis than those receiving a chitosan-formulated DNA vaccine. Increased dendritic cell (DC) maturation in the mesenteric lymph node (MLN) was observed in the mice vaccinated with VSV-VP1, which could be a potential mechanism for the protective immune response. These findings support VSV as a viral delivery vector that can induce robust mucosal immunity that should be considered for further vaccine development.

• 出版日期2014-6-30
• 单位河北医科大学; 苏州大学